Aptiv: Versigent Spin-Off and Wind River Valuation Create Asymmetric Upside for Long-Term Investors

UBS analyst Joseph Spak maintained a Buy rating on Aptiv yesterday and set a price target of $97.00.

Joseph Spak has given his Buy rating due to a combination of factors, notably his view that Aptiv’s current share price does not fully reflect the value that should be unlocked through the planned Versigent spin-off. In his sum-of-the-parts framework, either the remaining Aptiv business looks attractively valued relative to peers given its superior growth, margin and return prospects, or Versigent is being implicitly valued at close to nothing, creating an appealing asymmetry in potential outcomes.

Spak also acknowledges investor concerns around the Wind River software unit and the valuation he assigns to it, but he argues that its specialized, safety-critical real-time operating systems and embedded ecosystem make the franchise more defensible than many generic software assets. Even if the market were to apply a lower multiple or heavily discount Wind River, his analysis suggests the downside impact on Aptiv’s target price would be limited, leaving the overall risk/reward profile skewed favorably for long-term investors.

In another report released on March 11, Wells Fargo also maintained a Buy rating on the stock with a $95.00 price target.